Targeted Therapy for Hepatocellular Carcinoma: What`s New?

Crossmark: check for updates

Authors

  • Haluk Yuzugullu Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Bos- ton, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Har- vard Medical School, Boston, MA, USA
  • Ozge Gursoy-Yuzugullu Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA Hepatocellular carcinoma (HCC), one of the most frequent neoplasms worldwide, causes more than 700,000 deaths per year, and is the third cause of cancer-related mortality.

DOI:

https://doi.org/10.17140/lroj-1-e001

Abstract

Hepatocellular carcinoma (HCC), one of the most frequent neoplasms worldwide, causes more than 700,000 deaths per year, and is the third cause of cancer-related mortality. HCC occurs after years of damage to hepatocytes with inflammatory conditions due to Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection resulting in chronic hepatitis and/or cirrhosis. The disease incidence is decreasing due to Hepatitis B Virus (HBV) vaccination, whereas rates are steadily increasing in Europe and United States possibly due to increased obesity and Hepatitis C Virus (HCV) infection.3 The latest antiviral drug, Sofosbuvir (Sovaldi, Gilead), has achieved notable success in clinical trials and approved against HCV and gives great hopes for treatment and hopefully preventing HCV induced liver cancer. Unfortunately, other risk factors like alcohol abuse, fungal toxins, obesity, and poor diet are also associated with HCC and will not be easily wiped out anytime soon.

References

Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Dis-ease Study 2010. Lancet. 2012; 380: 2095-2128. doi: 10.1016/ S0140-6736(12)61728-0

Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: rea-sons for phase III failure and novel perspectives on trial design. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20: 2072-2079. doi: 10.1158/1078-0432.CCR-13-0547

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinician. 2011; 61: 69-90. doi: 10.3322/caac.20107

Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor Page e2 tyrosine kinase signaling. Mol Cancer Ther. 2008; 7: 3129-3140. doi: 10.1158/1535-7163.MCT-08-0013

Cleary SP, Jeck WR, Zhao X, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepa-tology. 2013; 58: 1693-1702. doi: 10.1002/hep.26540

Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature ge-netics. 2012; 44: 694-698. doi: 10.1038/ng.2256

Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing iden-tifies recurrent mutations in hepatocellular carcinoma. Genome research. 2013; 23: 1422-1433. doi: 10.1101/gr.154492.113

Nault JC, Mallet M, Pilati C, et al. High frequency of telom-erase reverse-transcriptase promoter somatic mutations in hepa-tocellular carcinoma and preneoplastic lesions. Nature commu-nications. 2013; 4: 2218. doi: 10.1038/ncomms3218

Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World journal of gastro-enterology : WJG21. 2015; 21(1): 311-317. doi: 10.3748/wjg. v21.i1.311

Santoro A. Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as sec-ond-line in patients (pts) with MET-high inoperable hepatocel-lular carcinoma (HCC). J Clin Oncol. 2013; 31(1).

Rudalska R, Dauch D, Longerich T, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nature medicine. 2014; 20: 1138-1146. doi: 10.1038/ nm.3679 Liver Res Open J Page e3

Downloads

Published

2015-04-20

How to Cite

Haluk Yuzugullu, & Ozge Gursoy-Yuzugullu. (2015). Targeted Therapy for Hepatocellular Carcinoma: What`s New?. Liver Research, 1(1), e1-e3. https://doi.org/10.17140/lroj-1-e001

Issue

Vol. 1 No. 1 (2015): Volume 1 Issue 1 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Liver Research (LROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.